Phosphodiesterase 10A inhibitors: A 2009 - 2012 patent update

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 1, 2013, Pages 31-45

  Kehler, Jan ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antipsychotic; Basal ganglia; Huntington's disease; Medium spiny neuron; Negative symptom; PDE10A; Phosphodiesterase 10A; Pro cognitive; Schizophrenia; Striatum

Indexed keywords

2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; MP-10; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE INHIBITOR; RADIOLIGAND; TAK 063; UNCLASSIFIED DRUG;

CROSS LINKING; DRUG DOSE; DRUG INDUSTRY; HUMAN; IC 50; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; COGNITION; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SCHIZOPHRENIA;

EID: 84871523977     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.739157     Document Type: Review

References (95)

1. Keravis T, Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 2012;165:1288-305
2. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91:651-90
3. Kehler J, Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 2011;17:137-50
4. Chappie TA, Helal CJ, Hou X. Current Landscape of Phosphodiesterase 10A (PDE10A) Inhibition. J Med Chem 2012;55(17):7299-331
5. Kehler J, Kilburn JP. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin Ther Patents 2009;19:1715-25
6. Kehler Jan, Ritzen A, Greve DR. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Patents 2007;17:147-58
7. H. Lundbeck A/S. WO2009152825; 2009
8. Kehler J, Ritzen A, Marigo M, et al. 4-Phenyl imidazoles: a novel class of phosphodiesterase 10A (PDE10A) inhibitors as a potential new generation of antipsychotics. Abstracts of Papers, 243rd ACS National Meeting & Exposition; 25 - 29 March 2012; San Diego, CA, United States; 2012; MEDI-296
9. H. Lundbeck A/S. WO2011072694; 2011
10. H. Lundbeck A/S. WO2011072695; 2011
11. H. Lundbeck A/S. WO2011072696; 2011
12. H. Lundbeck A/S. WO2011072697; 2011
13. H. Lundbeck A/S. WO2012000519; 2011
14. H. Lundbeck A/S. WO2012007006; 2011
15. Asproni B, Murineddu G, Pau A. Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c] quinazolines as potent phosphodiesterase 10A inhibitors. Bioorg Med Chem 2011;19:642-9
16. Kehler J, Ritzen A, Langgard M. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem Lett 2011;21:3738-42
17. H. Lundbeck A/S.WO2012065612; 2011
18. Merck. WO2010138430; 2010
19. Raheem IT, Breslin MJ, Fandozzi C, et al. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 2012;22(18):5903-8
20. Smith SM, Uslanerb JM, Cox CD, et al. The novel phosphodiesterase 10A inhibitor THPP-1has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 2013;64(1):215-23
21. Merck. WO2011022213; 2011
22. Merck. WO2010138585; 2010
23. Merck. WO2011053559; 2011
24. Merck. WO2012044561; 2012
25. Merck. WO2012044562; 2012
26. Merck. WO2012054366; 2012
27. Merck. WO2012058133; 2012
28. Merck (Schering Corp.). WO2010062559; 2010
29. McElroy WT, Tan Z, Basu K, et al. Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound. Bioorg Med Chem Lett 2012;22:1335-9
30. Ho GD, Yang S-W, Smotryski J, et al. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. Bioorg Med Chem Lett 2012;22:1019-22
31. Yang S-W, Smotryski J, McElroy WT, et al. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg Med Chem Lett 2012;22:235-9
32. Merck (Schering Corp.). WO2010117926; 2010
33. Merck (N. V. Organon; Schering Corp.). WO2011008597; 2011
34. Ho GD, Seganish MW, Bercovici A, et al. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg Med Chem Lett 2012;22: 2585-9
35. Omeros Corp. WO2009143178; 2009
36. Omeros Corp. WO2010017236; 2010
37. Gage JL, Onrust R, Johnston D, et al. N-Acylhydrazones as inhibitors of PDE10A. Bioorg Med Chem Lett 2012;21:4155-9
38. Cutshall NS, Onrust R, Rohde A, et al. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. Bioorg Med Chem Lett 2012;22:5595-9
39. Omeros Corp. WO2011112828; 2011
40. Envivo Pharmaceuticals, Inc. WO2009158473; 2009
41. Envivo Pharmaceuticals, Inc. WO2009158393; 2009
42. Envivo Pharmaceuticals, Inc. WO2009158467; 2009
43. Envivo Pharmaceuticals, Inc. WO2010006130; 2010
44. F. Hoffmann-La Roche AG. WO2010063610; 2010
45. F. Hoffmann-La Roche AG. WO2010094762; 2010
46. F. Hoffmann-La Roche AG. US20110071128; 2011
47. F. Hoffmann-La Roche AG. WO2011117264; 2011
48. F. Hoffmann-La Roche AG. US20120142665; 2012
49. F. Hoffmann-La Roche AG. WO2011089132; 2011
50. F. Hoffmann-La Roche AG. WO2011154327; 2011
51. Biotie/Wyeth. WO2010138833; 2010
52. Malamas MS, Ni Y, Erdei J, et al. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J Med Chem 2011;54:7621-38
53. Biotie/Wyeth. WO2010054260; 2010
54. Biotie/Wyeth. WO2010054253; 2010
55. Hofgen N, Stange H, Schindler R, et al. Discovery of Imidazo[1,5-a] pyrido[3,2-e] pyrazines as a new class ofphosphodiesterase 10A inhibitors. J Med Chem 2010;5: 4399-411
56. Biocrea/Boehringer Ingelheim. WO2012104293; 2012
57. Glenmark Pharmaceuticals Ltd. WO2011132048; 2011
58. Glenmark Pharmaceuticals Ltd. WO2011138657; 2011
59. Glenmark Pharmaceuticals Ltd. WO2011132051; 2011
60. Glenmark Pharmaceuticals Ltd. IN2009MU03042; 2012
61. Takeda Pharmaceutical Co. Ltd. US20100197651; 2010
62. Takeda Pharmaceutical Co. Ltd. WO2012018059; 2012
63. Takeda Pharmaceutical Co. Ltd. WO2012018058; 2012
64. Takeda Pharmaceutical Co. Ltd. WO2012020780; 2012
65. Takeda Pharmaceutical Co. Ltd. WO2011163355; 2011
66. Takeda Pharmaceutical Co. Ltd. WO2012018909; 2012
67. Janssen Pharmaceutica NV, BELG. WO2011051342; 2011
68. Janssen Pharmaceutica NV, BELG. WO2011110545; 2011
69. Sunovion Pharmaceuticals, Inc. WO2011150156; 2011
70. Sunovion Pharmaceuticals, Inc. US20120178748; 2012
71. Mitsubishi Tanabe Pharma Corp. WO2010027097; 2010
72. Mitsubishi Tanabe Pharma Corp. WO2010030027; 2010
73. Mitsubishi Tanabe Pharma Corp. WO2011105628; 2011
74. Andersen OA, Schoenfeld DL, Toogood-Johnson I, et al. Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure. Acta Crystallogr D Biol Crystallogr 2009;D65(8):872-4
75. Law R, Barker O, Barker JJ, et al. The multiple roles of computational chemistry in fragment-based drug design. J Comput Aided Mol Des 2009;23:459-73
76. Evotec (UK) Ltd. WO2012019954; 2012
77. Amgen, Inc. WO2010057126; 2010
78. Amgen, Inc. WO2010057121; 2010
79. Amgen, Inc. US20100160280; 2010
80. Amgen, Inc. WO2011143365; 2011
81. Amgen, Inc. WO2011143366; 2011
82. Amgen, Inc. WO2011143495; 2011
83. Amgen, Inc. WO2011143129; 2011
84. Janssen Pharmaceutica NV. WO2010097367; 2010
85. Janssen Pharmaceutica NV. WO2011051324; 2011
86. Celen S, Koole M, De AM, et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 2010;51:1584-91
87. Andres J-I, Angelis MD, Alcazar J, et al. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10inhibitors as candidates for positron emission tomography imaging. J Med Chem 2011;54:5820-35
88. Merck Sharp & Dohme Corp. WO2010138577; 2010
89. H. Lundbeck A/S. WO2012062319; 2012
90. Tu Z, Xu J, Jones LA, et al. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl Med Biol 2010;37:509-16
91. Tu Z, Fan J, Li S, et al. Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem 2011;19:1666-73
92. Funke U, Deuther-Conrad W, Schwan G, et al. Radiosynthesis and radiotracer properties of a 7-(2-[18F] Fluoroethoxy)-6- methoxypyrrolidinylquinazoline for imaging of phosphodiesterase 10A with PET. Pharmaceuticals 2012;5:169-88
93. Hu E, Ma J, Biorn C, et al. Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. J Med Chem 2012;5:4776-87
94. AstraZeneca. Bauer U, Giordanetto F, Bauer M. Discovery of 4-hydroxy-1, 6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors. Bioorg Med Chem Lett 2012;22:1944-8
95. DeMartinis N, Banerjee A, Kumar V, et al. Results of a Phase 2a Proof-of-Concept Trial with a PDE10A Inhibitor in the Treatment of Acute Exacerbation of Schizophrenia. Society of Biological Psychiatry 67th Annual Scientific Convention & Meeting; 3-5 May 2012; Sheraton Philadelphia Downtown Hotel-Philadelphia, Pennsylvania